ENZALUTAMIDE (has an active metabolite) | ENZALUTAMIDE | ATC L02BB04
ANTINEOPLASTIC ANDROGEN RECEPTOR INHIBITOR TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DECREASED PROLIFERATION AND INDUCED CELL DEATH | ORAL | Cmax 35.7 MICROMOLAR Tmax 1 HOUR VD 110 LITER PPB 97 PERCENT Cl 0.56 LITER / HOUR HT 139 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN WATER | ANDROGEN RECEPTOR (AR) | Androgen receptor UNIPROT P10275 AR more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |